Drug Manufacturing

Takeda Pharmaceutical concludes sale of OTC and non-core assets to Orifarm for $670m

Takeda Pharmaceutical Company has completed the previously announced sale of a portfolio of select over-the-counter (OTC) pharma products and non-core assets to Orifarm Group for $670m.

Fidia Farmaceutici acquires Sanofi’s anti-inflammatory drugs portfolio

Italian pharmaceutical company Fidia Farmaceutici has signed a binding agreement to acquire an integrated portfolio of anti-inflammatory drugs from Sanofi.

USFDA approves Janssen’s PONVORY for treatment of multiple sclerosis

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

Boston Pharmaceuticals signs three-year agreement with GSK

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK).

Ambrx gets orphan drug designation for gastric cancer treatment ARX788

The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.

Enveric Biosciences signs licensing agreement with Diverse Biotech

Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating diseases.

WuXi AppTec acquires OXGENE to develop cell and gene therapy services

WuXi AppTec has acquired OXGENE, a contract research and development organisation in the UK, to strengthen cell and gene therapy service offerings for global customers.

Sandoz to acquire GlaxoSmithKline’s cephalosporin antibiotics business

Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.

AstraZeneca signs LOI with IDT Biologika to boost Europe’s Covid-19 vaccine-making capability

Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine manufacturing capability.